MYOC and glaucoma: Building on these advances, our laboratory is now focused on designing and optimizing LNP formulations for targeted and efficient delivery of Cas9 mRNA to the TM, with the goal of editing disease-causing MYOC mutations in a mouse model of glaucoma.